Role of rosiglitazone in experimental Wistar rats model of neurodegeneration: Effect of peroxisome proliferator-activated receptors-γ as advanced glycation endproducts receptor of advanced glycation endproducts axis inhibitor

Objectives: The interaction between advanced glycation end products (AGEs) and their receptor of AGE (RAGE) contributes to various disorders, which impact neurological conditions and cognitive function. This work aims to explore the potential treatment using rosiglitazone to address these conditions. Materials and Methods: The animal study was conducted on four different groups of male albino Wistar rats, each group containing six rats. Treatment of group 1 was saline (0.9%), group 2 was haloperidol (1 mg/kg/day) for 28-day intraperitoneal route, group 3 was haloperidol and rosiglitazone (10 mg/kg/day) for 28 days and group 4 was treated with the drug rosiglitazone (10 mg/kg/day) for 28 days. The test procedure was made so that the disease was induced using haloperidol, and treatment was done with the peroxisome proliferator-activated receptors-γ (PPAR-γ) blocker rosiglitazone. This study utilised adult male Wistar rats to investigate the effects of rosiglitazone on haloperidol-induced neurodegeneration. Results: The results from the behavioural parameters, antioxidant parameters and AGE-RAGE parameters indicate the action of rosiglitazone on the receptor of AGE and suppression of neurodegenerative disorder. Urine output and body weight improved in addition to rosiglitazone. Rosiglitazone improves the retention time (663.5 s) on the rotarod and the Morris water maze apparatus. The drug rosiglitazone acts on the reduction of free radicals, thus reducing the oxidant stress and also reducing diseased conditions. The level of interleukin-6, thrombosis necrosis factor-α and amyloid-β protein was significantly reduced with the help of rosiglitazone. Conclusion: The results conclude that the effect of PPAR-γ blocker drugs can act by reducing the effect produced by the advanced glycation end product and blocking the receptor of the advanced glycation end product to cure neurological conditions.